Israeli Researchers Discover Viagra Can Stop Cancer Spread

Researchers at the Weizmann Institute of Science in Israel have identified a mechanism where sildenafil, the active ingredient in Viagra, may inhibit the spread of certain cancer cells. According to reporting by Med Israel för fred (MIFF) on August 10, 2026, the study suggests the drug can interfere with the process of metastasis, which is the movement of cancer from a primary site to other parts of the body.

The findings focus on how sildenafil affects the cellular pathways that allow tumors to migrate. While primarily known as a treatment for erectile dysfunction and pulmonary arterial hypertension, the drug’s impact on blood flow and specific enzyme inhibitors has led scientists to investigate its potential as a repurposed oncology tool.

Sildenafil’s Impact on Cancer Metastasis

The research conducted at the Weizmann Institute indicates that sildenafil targets the mechanisms that cancer cells use to break away from the original tumor. According to the report, this inhibition could potentially slow or stop the progression of the disease in patients where metastasis is a primary risk.

Metastasis remains one of the most lethal aspects of cancer, as it often renders localized treatments like surgery or radiation less effective. By blocking the signals that trigger cell migration, the researchers aim to limit the systemic spread of the malignancy.

The Role of the Weizmann Institute Research

The Weizmann Institute of Science is a leading multidisciplinary research institution known for its work in molecular biology and genetics. In this specific study, researchers analyzed how phosphodiesterase type 5 (PDE5) inhibitors, the class of drugs to which sildenafil belongs, interact with the signaling pathways of cancer cells.

PDE5 inhibitors increase the levels of cyclic guanosine monophosphate (cGMP) in cells. According to the scientific framework of the study, elevated cGMP levels can interfere with the proteins and enzymes that cancer cells utilize to reshape their cytoskeleton, a necessary step for movement and invasion into surrounding tissues.

Repurposing Existing Medications for Oncology

The use of sildenafil in this context is part of a broader medical trend called drug repurposing. This process involves identifying new therapeutic uses for medications that have already been approved by regulators for other conditions, which can significantly shorten the timeline for clinical trials.

Because the safety profile and pharmacological properties of sildenafil are well-documented over decades of use, researchers can focus specifically on the dosage and efficacy required to inhibit cancer cell migration rather than starting from a new chemical entity.

Limitations and Future Clinical Application

While the initial results are promising, the research is currently in a stage that requires further validation. The report does not state that sildenafil is a replacement for standard chemotherapy or immunotherapy, nor does it suggest that the drug can eliminate existing tumors entirely.

Future steps for the Weizmann Institute researchers involve determining which specific types of cancer respond best to this treatment. The effectiveness of sildenafil may vary depending on the genetic makeup of the tumor and the specific pathways it uses to metastasize.

Clinical trials will be necessary to establish whether the concentrations of the drug required to stop cancer spread are safe and sustainable for long-term use in oncology patients.